A Trial With an Endpoint Already Named
A 31-year-old with idiopathic low-count sperm and testosterone that reads low-normal, not clearly deficient — testing whether an empiric hormonal trial is defensible medicine or just a plausible-sounding habit.
Julian M. and his partner have been trying to conceive for eleven months, past the point where most guidelines recommend a fertility workup, and his own contribution to that workup came back with oligospermia — a sperm concentration of 9 million per milliliter, below the normal reference range but not severely so — discovered on the semen analysis obtained after his partner's own evaluation came back entirely normal. Julian works as a high school chemistry teacher and coaches the school's robotics team most afternoons; nothing in his history points to an obvious cause — no varicocele on exam, no history of cryptorchidism, chemotherapy, or significant heat exposure, no medications known to affect spermatogenesis.
His testosterone came back at 340 ng/dL, low-normal rather than clearly deficient, with LH and FSH both within normal range — a pattern that doesn't meet the biochemical definition of hypogonadism the way Devon R.'s case elsewhere in this volume does, which matters directly to what's actually being proposed here. Clomiphene's real, better-established use is in men with confirmed secondary hypogonadism and a genuinely low testosterone that an upstream nudge can meaningfully correct. Julian's numbers sit inside the normal range on every axis; what's being proposed for him is an empiric trial aimed purely at improving semen parameters in a man whose hormone panel doesn't show clear deficiency to begin with, which is a meaningfully different claim than the fertility-preservation use in Case 2 of this volume.
Multiple systematic reviews, including repeated Cochrane assessments over more than a decade, have found the trial evidence for anti-estrogens including clomiphene in idiopathic male infertility genuinely insufficient to confirm a real effect on pregnancy or live birth rates, even where individual small trials have shown modest improvement in sperm concentration or motility alone. That gap — a plausible surrogate-endpoint signal without a confirmed effect on the outcome that actually matters to Julian and his partner — is the entire tension in his case. The intervention is inexpensive, low-risk, and widely used in real-world reproductive urology practice regardless of that evidence gap, which is itself worth naming honestly rather than either overselling or dismissing.
Fertility clinic, naming what the evidence actually shows
Idiopathic oligospermia with a normal hormone panel is exactly the picture where empiric clomiphene gets used in real-world practice, and it's genuinely common — low risk, inexpensive, and a real fraction of men see a meaningful semen-parameter improvement. Given they've already passed eleven months of trying, a defined three-month trial with a clear endpoint is a reasonable next step while they continue.
I want to be precise about what that trial evidence actually shows, because I think the framing matters to how we counsel them. Repeated systematic reviews, including several Cochrane assessments over more than a decade, have found insufficient high-quality evidence that anti-estrogens improve pregnancy or live birth rates in idiopathic male infertility — the positive signal that does exist is mostly in semen parameters, a surrogate outcome, not the outcome Julian and his partner actually care about.
I'm not arguing against offering it — I'm arguing against letting them believe the evidence for a baby is as solid as the evidence for a better sperm count on paper. Those are genuinely different claims.
Then the honest version of this offer is the right one: clomiphene for three months, semen analysis repeated at the end of that window, and an explicit conversation before starting that this may improve his numbers without being proven to change their odds of conceiving. If it doesn't move his semen parameters at all by three months, that's a real signal to stop rather than continue indefinitely on a plausible mechanism alone.
Agreed: a bounded twelve-week clomiphene trial with a repeat semen analysis as the explicit stopping point, and a documented conversation with Julian and his partner distinguishing the drug's real semen-parameter evidence from its unproven effect on pregnancy or live birth — so the offer itself, not just the outcome, was made honestly.
The reproductive urologist's underlying practice pattern — that empiric clomiphene is common and reasonable here — was not disputed; what changed was how it was framed to the patient, with the evidence gap named up front rather than left implicit.